581 related articles for article (PubMed ID: 11743206)
1. Correction of sickle cell disease in transgenic mouse models by gene therapy.
Pawliuk R; Westerman KA; Fabry ME; Payen E; Tighe R; Bouhassira EE; Acharya SA; Ellis J; London IM; Eaves CJ; Humphries RK; Beuzard Y; Nagel RL; Leboulch P
Science; 2001 Dec; 294(5550):2368-71. PubMed ID: 11743206
[TBL] [Abstract][Full Text] [Related]
2. Progress toward the genetic treatment of the beta-thalassemias.
Sadelain M; Lisowski L; Samakoglu S; Rivella S; May C; Riviere I
Ann N Y Acad Sci; 2005; 1054():78-91. PubMed ID: 16339654
[TBL] [Abstract][Full Text] [Related]
3. Adeno-associated virus 2-mediated transduction and erythroid lineage-restricted long-term expression of the human beta-globin gene in hematopoietic cells from homozygous beta-thalassemic mice.
Tan M; Qing K; Zhou S; Yoder MC; Srivastava A
Mol Ther; 2001 Jun; 3(6):940-6. PubMed ID: 11407908
[TBL] [Abstract][Full Text] [Related]
4. Expression of an anti-sickling beta-globin in human erythroblasts derived from retrovirally transduced primitive normal and sickle cell disease hematopoietic cells.
Oh IH; Fabry ME; Humphries RK; Pawliuk R; Leboulch P; Hoffman R; Nagel RL; Eaves C
Exp Hematol; 2004 May; 32(5):461-9. PubMed ID: 15145214
[TBL] [Abstract][Full Text] [Related]
5. Gene therapy. Gene gemisch cures sickle cell in mice.
Marshall E
Science; 2001 Dec; 294(5550):2268. PubMed ID: 11743172
[No Abstract] [Full Text] [Related]
6. A phase I/II clinical trial of beta-globin gene therapy for beta-thalassemia.
Bank A; Dorazio R; Leboulch P
Ann N Y Acad Sci; 2005; 1054():308-16. PubMed ID: 16339679
[TBL] [Abstract][Full Text] [Related]
7. Anti-beta s-ribozyme reduces beta s mRNA levels in transgenic mice: potential application to the gene therapy of sickle cell anemia.
Alami R; Gilman JG; Feng YQ; Marmorato A; Rochlin I; Suzuka SM; Fabry ME; Nagel RL; Bouhassira EE
Blood Cells Mol Dis; 1999 Apr; 25(2):110-9. PubMed ID: 10389593
[TBL] [Abstract][Full Text] [Related]
8. A novel transgenic mouse model produced from lentiviral germline integration for the study of beta-thalassemia gene therapy.
Li W; Xie S; Guo X; Gong X; Wang S; Lin D; Zhang J; Ren Z; Huang S; Zeng F; Zeng Y
Haematologica; 2008 Mar; 93(3):356-62. PubMed ID: 18268280
[TBL] [Abstract][Full Text] [Related]
9. Successful correction of the human Cooley's anemia beta-thalassemia major phenotype using a lentiviral vector flanked by the chicken hypersensitive site 4 chromatin insulator.
Malik P; Arumugam PI; Yee JK; Puthenveetil G
Ann N Y Acad Sci; 2005; 1054():238-49. PubMed ID: 16339671
[TBL] [Abstract][Full Text] [Related]
10. A transgenic mouse model of sickle cell disorder.
Greaves DR; Fraser P; Vidal MA; Hedges MJ; Ropers D; Luzzatto L; Grosveld F
Nature; 1990 Jan; 343(6254):183-5. PubMed ID: 2296310
[TBL] [Abstract][Full Text] [Related]
11. Gene therapy for the hemoglobin disorders.
Persons DA; Nienhuis AW
Curr Hematol Rep; 2003 Jul; 2(4):348-55. PubMed ID: 12901333
[TBL] [Abstract][Full Text] [Related]
12. Recent advances in globin gene transfer for the treatment of beta-thalassemia and sickle cell anemia.
Sadelain M
Curr Opin Hematol; 2006 May; 13(3):142-8. PubMed ID: 16567956
[TBL] [Abstract][Full Text] [Related]
13. In vivo silencing of the human gamma-globin gene in murine erythroid cells following retroviral transduction.
Lung HY; Meeus IS; Weinberg RS; Atweh GF
Blood Cells Mol Dis; 2000 Dec; 26(6):613-9. PubMed ID: 11358353
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin.
May C; Rivella S; Callegari J; Heller G; Gaensler KM; Luzzatto L; Sadelain M
Nature; 2000 Jul; 406(6791):82-6. PubMed ID: 10894546
[TBL] [Abstract][Full Text] [Related]
15. Globin gene transfer for treatment of the beta-thalassemias and sickle cell disease.
Sadelain M; Rivella S; Lisowski L; Samakoglu S; Rivière I
Best Pract Res Clin Haematol; 2004 Sep; 17(3):517-34. PubMed ID: 15498721
[TBL] [Abstract][Full Text] [Related]
16. Genetic correction of sickle cell disease: insights using transgenic mouse models.
Blouin MJ; Beauchemin H; Wright A; De Paepe M; Sorette M; Bleau AM; Nakamoto B; Ou CN; Stamatoyannopoulos G; Trudel M
Nat Med; 2000 Feb; 6(2):177-82. PubMed ID: 10655106
[TBL] [Abstract][Full Text] [Related]
17. Mouse models of sickle cell disease.
Beuzard Y
Transfus Clin Biol; 2008; 15(1-2):7-11. PubMed ID: 18502677
[TBL] [Abstract][Full Text] [Related]
18. Comparative analysis of FV vectors with human α- or β-globin gene regulatory elements for the correction of β-thalassemia.
Morianos I; Siapati EK; Pongas G; Vassilopoulos G
Gene Ther; 2012 Mar; 19(3):303-11. PubMed ID: 21734726
[TBL] [Abstract][Full Text] [Related]
19. Gene Therapy for Sickle Cell Disease: A Lentiviral Vector Comparison Study.
Urbinati F; Campo Fernandez B; Masiuk KE; Poletti V; Hollis RP; Koziol C; Kaufman ML; Brown D; Mavilio F; Kohn DB
Hum Gene Ther; 2018 Oct; 29(10):1153-1166. PubMed ID: 30198339
[TBL] [Abstract][Full Text] [Related]
20. Progress toward safe and effective gene therapy for beta-thalassemia and sickle cell disease.
Lebensburger J; Persons DA
Curr Opin Drug Discov Devel; 2008 Mar; 11(2):225-32. PubMed ID: 18283610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
